Investors & Media

Press Releases

Press Releases

Date Title View
Toggle Summary Sage Therapeutics to Present at the Stifel 3rd Annual CNS Day
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 24, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will
View HTML
Toggle Summary Sage Therapeutics Announces Continued Positive Zuranolone Data for Both 30 mg and 50 mg Doses in Open-Label SHORELINE Study in Patients with MDD
In the now completed 30 mg zuranolone cohort, approximately 70% of participants with positive response to an initial 2-week treatment required at most one additional zuranolone treatment during the 12-month study After the initial 2-week zuranolone treatment, more than 70% of patients who received
View HTML
Toggle Summary Sage Therapeutics Announces Departure of Chief Operating Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2021-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating brain disorders, today announced that Mike Cloonan , Sage’s Chief Operating
View HTML
Toggle Summary Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
Reported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year Progressed WATERFALL Study – now closed to enrollment – investigating zuranolone for as needed
View HTML
Toggle Summary Sage Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2021-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast
View HTML
Toggle Summary Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference
Catalyst rich 2021 includes expected topline readouts from ten clinical trials across the Company’s depression, neurology and neuropsychiatry franchises and in COVID-related ARDS Company committed to accelerating pipeline and expanding product engine with goal of delivering at least two
View HTML
Toggle Summary Sage Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML
Toggle Summary Sage Therapeutics Announces the Appointment of Barry Greene as CEO
Barry Greene , a world-class leader with global experience and a significant track record of success in R&D and commercialization, joins as part of plan to accelerate the Sage mission to deliver truly transformational medicines for people with brain health disorders Jeff Jonas to assume new role of
View HTML
Toggle Summary Sage Therapeutics to Present at BMO 2020 Growth & ESG Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present
View HTML